|
|
|
|
|
|
| TOP STORY |
 |
|
Vaccine Production Key to Global Pandemic Response |
Biopharma companies have been working overtime to supply billions of doses of any safe and effective preventive. But the tight timeframe means they can't wait for final clinical test results to begin preparing large-scale manufacturing operations and to address critical supply chain issues, writes Jill Wechsler
… /Read more/ |
|
|
|
|
|
|
| Advertisement |
Now and Next: A COVID-19 Access and Patient Engagement Update
Thursday, May 28, 2020 at 11am EDT
Register now
|
| |
| Industry update |
| //Rare disease company Centogene (Cambridge, MA, and Rostock/Berlin, Germany) announced that Mr. Oved Amitay will be stepping down as Chief Business Officer and leaving the company effective May 31, 2020. He will be succeeded by Mr. Sun Kim, Centogene's current Chief Strategy and IR Officer, who will assume Mr. Amitay’s responsibilities as CBO until a permanent CBO has been appointed.
//Phillips-Medisize (Hudson, WI) appointed Paul Chaffin as Senior Vice President and President of the Medical and Pharmaceutical Solutions division of Molex.
//Cellectis (New York, NY), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells appointed Leopold Bertea, Ph.D., as Senior Vice President of Technical Operations – Europe.
|
|
|
|
|
|
|
|
|
|
|
